Rosabulin is primarily investigated for its potential in cancer therapy due to its ability to disrupt microtubule dynamics, which are crucial for cell division. By targeting and destabilizing microtubules, it can inhibit the proliferation of cancer cells, making it a promising candidate for treating various types of cancers. Research is ongoing to evaluate its efficacy and safety in clinical settings, with a focus on its potential to overcome resistance to existing microtubule-targeting agents. Additionally, studies explore its application in combination therapies to enhance overall treatment outcomes.